Literature DB >> 10725728

Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines.

B P Arulanandam1, J N Mittler, W T Lee, M O'Toole, D W Metzger.   

Abstract

Neonates are highly susceptible to infectious agents and are known to display polarized expression of Th2-like cytokines and Abs. This neonatal immune bias has important implications for the development of vaccine strategies, particularly against viral infections. We now report that coadministration of IL-12 and an influenza subunit vaccine at birth enhances the protective efficacy of antiviral vaccination. Immunization and treatment with IL-12 within 24 h of birth resulted in elevated expression of IFN-gamma, IL-10, and IL-15 mRNA in the spleens of newborn mice compared with animals exposed to vaccine only. In addition, these animals showed dramatic increases in IFN-gamma-, IL-2-, and IL-4-secreting cells, and in IgG2a Ab levels upon adult challenge compared with mice primed with vaccine alone. Most importantly, animals vaccinated and simultaneously treated with IL-12 at birth displayed enhanced survival after lethal challenge with infectious influenza virus as adults compared with infected animals that had been primed with vaccine alone. This augmented protection required B cells and could be transferred to naive mice by immune serum. Collectively, these results provide evidence that administration of IL-12 to neonates induces a Th1-like response in newborns and elicits protective antiviral immune memory.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725728     DOI: 10.4049/jimmunol.164.7.3698

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Neonatal dendritic cells are intrinsically biased against Th-1 immune responses.

Authors:  C L Langrish; J C Buddle; A J Thrasher; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  The anti-tetanus immune response of neonatal mice is augmented by retinoic acid combined with polyriboinosinic:polyribocytidylic acid.

Authors:  Yifan Ma; A Catharine Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

3.  EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function.

Authors:  K Bickham; C Münz; M L Tsang; M Larsson; J F Fonteneau; N Bhardwaj; R Steinman
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

4.  The migration of T cells in response to influenza virus is altered in neonatal mice.

Authors:  J Louise Lines; Samantha Hoskins; Melissa Hollifield; Linda S Cauley; Beth A Garvy
Journal:  J Immunol       Date:  2010-07-23       Impact factor: 5.422

Review 5.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

6.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

7.  Susceptibility to polyomavirus-induced tumors in inbred mice: role of innate immune responses.

Authors:  Palanivel Velupillai; John P Carroll; Thomas L Benjamin
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Localization of the T-cell response to RSV infection is altered in infant mice.

Authors:  Katherine M Eichinger; Jessica L Kosanovich; Kerry M Empey
Journal:  Pediatr Pulmonol       Date:  2017-11-08

Review 9.  Safety and efficacy of neonatal vaccination.

Authors:  Alicia Demirjian; Ofer Levy
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

10.  Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.

Authors:  Joyce M Lynch; David E Briles; Dennis W Metzger
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.